ALKBH5 promotes invasion and metastasis of gastric ca the lncRNA NEAT1

Journal of Physiology and Biochemistry 75, 379-389 DOI: 10.1007/s13105-019-00690-8

Citation Report

#	Article	IF	CITATIONS
1	N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancers: roles, mechanisms, and applications. Molecular Cancer, 2019, 18, 178.	7.9	72
2	ALKBH5-m6A-FOXM1 signaling axis promotes proliferation and invasion of lung adenocarcinoma cells under intermittent hypoxia. Biochemical and Biophysical Research Communications, 2020, 521, 499-506.	1.0	101
3	BMP2 Modified by the m6A Demethylation Enzyme ALKBH5 in the Ossification of the Ligamentum Flavum Through the AKT Signaling Pathway. Calcified Tissue International, 2020, 106, 486-493.	1.5	27
4	Joint analysis of IncRNA m6A methylome and IncRNA/mRNA expression profiles in gastric cancer. Cancer Cell International, 2020, 20, 464.	1.8	22
5	LncRNA PCAT18/miR-301a/TP53INP1 axis is involved in gastric cancer cell viability, migration and invasion. Journal of Biochemistry, 2020, 168, 547-555.	0.9	6
6	Dexmedetomidine Suppressed the Biological Behavior of HK-2 Cells Treated with LPS by Down-Regulating ALKBH5. Inflammation, 2020, 43, 2256-2263.	1.7	25
7	RNA methylations in human cancers. Seminars in Cancer Biology, 2021, 75, 97-115.	4.3	87
8	PTEN, a Barrier for Proliferation and Metastasis of Gastric Cancer Cells: From Molecular Pathways to Targeting and Regulation. Biomedicines, 2020, 8, 264.	1.4	40
9	Crosstalk between RNA m6A Modification and Non-coding RNA Contributes to Cancer Growth and Progression. Molecular Therapy - Nucleic Acids, 2020, 22, 62-71.	2.3	59
10	Novel insights into the interplay between m6A modification and noncoding RNAs in cancer. Molecular Cancer, 2020, 19, 121.	7.9	148
11	Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation. Frontiers in Oncology, 2020, 10, 1126.	1.3	89
12	The biological function of m6A demethylase ALKBH5 and its role in human disease. Cancer Cell International, 2020, 20, 347.	1.8	108
13	To Develop and Validate the Combination of RNA Methylation Regulators for the Prognosis of Patients with Gastric Cancer. OncoTargets and Therapy, 2020, Volume 13, 10785-10795.	1.0	13
14	Emerging roles of RNA methylation in gastrointestinal cancers. Cancer Cell International, 2020, 20, 585.	1.8	65
15	Non-Coding RNAs as Mediators of Epigenetic Changes in Malignancies. Cancers, 2020, 12, 3657.	1.7	64
16	meCLICK-Seq, a Substrate-Hijacking and RNA Degradation Strategy for the Study of RNA Methylation. ACS Central Science, 2020, 6, 2196-2208.	5.3	31
17	RNA m6A Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications. Innovation(China), 2020, 1, 100066.	5.2	69
18	RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia. Cell Stem Cell, 2020, 27, 64-80.e9.	5.2	225

#	Article	IF	CITATIONS
19	RNA N-6-methyladenosine enzymes and resistance of cancer cells to chemotherapy and radiotherapy. Epigenomics, 2020, 12, 801-809.	1.0	32
20	ALKBH5 promotes the proliferation of renal cell carcinoma by regulating AURKB expression in an m6A-dependent manner. Annals of Translational Medicine, 2020, 8, 646-646.	0.7	53
21	Mechanism of RNA modification N6-methyladenosine in human cancer. Molecular Cancer, 2020, 19, 104.	7.9	184
22	m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell, 2020, 37, 270-288.	7.7	688
23	Epigenetic modulations of noncoding RNA: a novel dimension of Cancer biology. Molecular Cancer, 2020, 19, 64.	7.9	69
24	Human and Arabidopsis alphaâ€ketoglutarateâ€dependent dioxygenase homolog proteins—New players in important regulatory processes. IUBMB Life, 2020, 72, 1126-1144.	1.5	22
25	The emerging roles of N6-methyladenosine RNA methylation in human cancers. Biomarker Research, 2020, 8, 24.	2.8	31
26	<i>ALKBH5</i> gene polymorphisms and Wilms tumor risk in Chinese children: A fiveâ€center caseâ€control study. Journal of Clinical Laboratory Analysis, 2020, 34, e23251.	0.9	19
27	N6-methyladenosine ALKBH5 promotes non-small cell lung cancer progress by regulating TIMP3 stability. Gene, 2020, 731, 144348.	1.0	68
28	m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling. Molecular Cancer, 2020, 19, 3.	7.9	206
29	Long Noncoding RNA NEAT1 Suppresses Proliferation and Promotes Apoptosis of Glioma Cells Via Downregulating MiR-92b. Cancer Control, 2020, 27, 107327481989797.	0.7	21
30	SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miRâ€⊋3bâ€3p via sponging EGR1 in hepatocellular carcinoma. Cancer Medicine, 2020, 9, 4324-4338.	1.3	28
31	Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer. Cancer Biology and Medicine, 2020, 17, 9-19.	1.4	26
32	VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer. Cancers, 2020, 12, 771.	1.7	59
33	Developing a risk scoring system based on immune-related lncRNAs for patients with gastric cancer. Bioscience Reports, 2021, 41, .	1.1	6
34	Use of bioinformatic database analysis and specimen verification to identify novel biomarkers predicting gastric cancer metastasis. Journal of Cancer, 2021, 12, 5967-5976.	1.2	6
35	Regulation of Gene Expression Associated With the N6-Methyladenosine (m6A) Enzyme System and Its Significance in Cancer. Frontiers in Oncology, 2020, 10, 623634.	1.3	27
36	Ribonucleotide base-modifying enzymes and diseases. , 2021, , 69-83.		1

#	Article	IF	CITATIONS
37	ALKBH5-mediated m6A demethylation of FOXM1 mRNA promotes progression of uveal melanoma. Aging, 2021, 13, 4045-4062.	1.4	27
38	LncRNA LIFR-AS1 promotes proliferation and invasion of gastric cancer cell via miR-29a-3p/COL1A2 axis. Cancer Cell International, 2021, 21, 7.	1.8	35
39	The role of m6A, m5C and $\hat{\Gamma}$ RNA modifications in cancer: Novel therapeutic opportunities. Molecular Cancer, 2021, 20, 18.	7.9	245
40	m6A RNA methylation regulators were associated with the malignancy and prognosis of ovarian cancer. Bioengineered, 2021, 12, 3159-3176.	1.4	23
41	The non-coding epitranscriptome in cancer. Briefings in Functional Genomics, 2021, 20, 94-105.	1.3	11
42	Methyladenosine Modification in RNAs: Classification and Roles in Gastrointestinal Cancers. Frontiers in Oncology, 2020, 10, 586789.	1.3	14
43	Prognostic and Predictive Value of m6A "Eraser―Related Gene Signature in Gastric Cancer. Frontiers in Oncology, 2021, 11, 631803.	1.3	15
44	RNA methylation in hematological malignancies and its interactions with other epigenetic modifications. Leukemia, 2021, 35, 1243-1257.	3.3	19
45	ALKBH5 Exacerbates Aortic Dissection by Promoting Inflammatory Response and Apoptosis of Aortic Smooth Muscle Cells via Regulating Inc-TMPO-AS1/EZH2/IRAK4 Signals in an m6A Modification Manner. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-24.	1.9	0
46	M6ADD: a comprehensive database of m ⁶ A modifications in diseases. RNA Biology, 2021, 18, 2354-2362.	1.5	8
47	The epitranscriptome of long noncoding RNAs in metabolic diseases. Clinica Chimica Acta, 2021, 515, 80-89.	0.5	19
48	Molecular Mechanism of 73HOXC-AS1-Activated Wntl²-Catenin Signaling and eIF4AIII in Promoting Progression of Gastric Cancer. BioMed Research International, 2021, 2021, 1-9.	0.9	4
49	NEAT1 siRNA Packed with Chitosan Nanoparticles Regulates the Development of Colon Cancer Cells via IncRNA NEAT1/miR-377-3p Axis. BioMed Research International, 2021, 2021, 1-8.	0.9	8
50	TYMSOS drives the proliferation, migration, and invasion of gastric cancer cells by regulating ZNF703 via sponging miRâ€4739. Cell Biology International, 2021, 45, 1710-1719.	1.4	20
51	Elucidating the Functions of Non-Coding RNAs from the Perspective of RNA Modifications. Non-coding RNA, 2021, 7, 31.	1.3	8
52	N ⁶ â€methyladenosine Steers RNA Metabolism and Regulation in Cancer. Cancer Communications, 2021, 41, 538-559.	3.7	24
53	ALKBH5-mediated m6A demethylation of IncRNA RMRP plays an oncogenic role in lung adenocarcinoma. Mammalian Genome, 2021, 32, 195-203.	1.0	29
54	Changes and relationship of N6-methyladenosine modification and long non-coding RNAs in oxidative damage induced by cadmium in pancreatic β-cells. Toxicology Letters, 2021, 343, 56-66.	0.4	19

#	Article	IF	CITATIONS
56	m5C-Related IncRNAs Predict Overall Survival of Patients and Regulate the Tumor Immune Microenvironment in Lung Adenocarcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 671821.	1.8	38
57	Potential roles of N6-methyladenosine (m6A) in immune cells. Journal of Translational Medicine, 2021, 19, 251.	1.8	36
58	The Role of Sex-specific Long Non-coding RNAs in Cancer Prevention and Therapy. Journal of Cancer Prevention, 2021, 26, 98-109.	0.8	8
59	Role of m6A in osteoporosis, arthritis and osteosarcoma (Review). Experimental and Therapeutic Medicine, 2021, 22, 926.	0.8	16
60	m6A RNA methylation and beyond – The epigenetic machinery and potential treatment options. Drug Discovery Today, 2021, 26, 2559-2574.	3.2	50
61	Function and clinical significance of N6-methyladenosine in digestive system tumours. Experimental Hematology and Oncology, 2021, 10, 40.	2.0	16
62	The differential diagnosis of pneumonia in two patients infected by atypical pathogens. Future Microbiology, 2021, 16, 769-776.	1.0	0
63	m6A modification of RNA and its role in cancer, with a special focus on lung cancer. Genomics, 2021, 113, 2860-2869.	1.3	19
64	A seven-m6A regulator-related CpG site-based prognostic signature for endometrial carcinoma. Medicine (United States), 2021, 100, e26648.	0.4	5
65	The m6A Methyltransferase METTL14-Mediated N6-Methyladenosine Modification of PTEN mRNA Inhibits Tumor Growth and Metastasis in Stomach Adenocarcinoma. Frontiers in Oncology, 2021, 11, 699749.	1.3	12
66	The detection and functions of RNA modification m6A based on m6A writers and erasers. Journal of Biological Chemistry, 2021, 297, 100973.	1.6	43
67	Differential analysis of RNA methylation regulators in gastric cancer based on TCGA data set and construction of a prognostic model. Journal of Gastrointestinal Oncology, 2021, 12, 1384-1397.	0.6	12
68	KIAA1429 and ALKBH5 Oppositely Influence Aortic Dissection Progression via Regulating the Maturation of Pri-miR-143-3p in an m6A-Dependent Manner. Frontiers in Cell and Developmental Biology, 2021, 9, 668377.	1.8	10
69	Integrative Analysis Reveals Potentially Functional N6-Methylandenosine-Related Long Noncoding RNAs in Colon Adenocarcinoma. Frontiers in Genetics, 2021, 12, 739344.	1.1	4
70	Deregulation of N6-Methyladenosine RNA Modification and Its Erasers FTO/ALKBH5 among the Main Renal Cell Tumor Subtypes. Journal of Personalized Medicine, 2021, 11, 996.	1.1	20
71	Long non-coding RNAs as a predictive markers of group 3 medulloblastomas. Neurological Research, 2022, 44, 232-241.	0.6	5
72	Emerging Roles of N6-Methyladenosine Demethylases and Its Interaction with Environmental Toxicants in Digestive System Cancers. Cancer Management and Research, 2021, Volume 13, 7101-7114.	0.9	3
73	N6-Methyladenosine and Rheumatoid Arthritis: A Comprehensive Review. Frontiers in Immunology, 2021, 12, 731842.	2.2	18

#	Article	IF	CITATIONS
74	Structural Insights Into m6A-Erasers: A Step Toward Understanding Molecule Specificity and Potential Antiviral Targeting. Frontiers in Cell and Developmental Biology, 2020, 8, 587108.	1.8	9
75	Prognostic Value of IncRNA NEAT1 as a New Biomarker in Digestive System Tumors: a Systematic Study and Meta-analysis. Expert Review of Molecular Diagnostics, 2021, 21, 91-99.	1.5	2
76	m(6)A mRNA Methylation Regulates Ferroptosis in HPSCC by Targeting NFE2L2/NRF2. SSRN Electronic Journal, 0, , .	0.4	0
77	Targeted point mutations of the m6A modification in miR675 using RNA-guided base editing induce cell apoptosis. Bioscience Reports, 2020, 40, .	1.1	7
78	Clinical and prognostic pan-cancer analysis of m6A RNA methylation regulators in four types of endocrine system tumors. Aging, 2020, 12, 23931-23944.	1.4	31
79	The m6A RNA Demethylase ALKBH5 Promotes Radioresistance and Invasion Capability of Glioma Stem Cells. Cancers, 2021, 13, 40.	1.7	59
80	Long noncoding RNAs in gastric cancer: From molecular dissection to clinical application. World Journal of Gastroenterology, 2020, 26, 3401-3412.	1.4	35
81	N6‑methyladenine RNA modification and cancer (Review). Oncology Letters, 2020, 20, 1504-1512.	0.8	25
82	Prediction and prognostic significance of ALOX12B and PACSIN1 expression in gastric cancer by genome-wide RNA expression and methylation analysis. Journal of Gastrointestinal Oncology, 2021, 12, 2082-2092.	0.6	3
83	Knockdown of METTL14 suppresses the malignant progression of non‑small cell lung cancer by reducing Twist expression. Oncology Letters, 2021, 22, 847.	0.8	15
84	N6-Methyladenosine-Sculpted Regulatory Landscape of Noncoding RNA. Frontiers in Oncology, 2021, 11, 743990.	1.3	6
85	The Role of Long Non-coding RNA, Nuclear Enriched Abundant Transcript 1 (NEAT1) in Cancer and Other Pathologies. Biochemical Genetics, 2022, 60, 843-867.	0.8	5
86	Role of RNA modification in gastrointestinal tumors. World Chinese Journal of Digestology, 2021, 29, 1179-1185.	0.0	0
87	LncRNA NEAT1/miR-204/NUAK1 Axis is a Potential Therapeutic Target for Non-Small Cell Lung Cancer. Cancer Management and Research, 2020, Volume 12, 13357-13368.	0.9	10
88	Development and validation of a three-long noncoding RNA signature for predicting prognosis of patients with gastric cancer. World Journal of Gastroenterology, 2020, 26, 6929-6944.	1.4	4
89	ALKBH5 promotes colon cancer progression by decreasing methylation of the IncRNA NEAT1. American Journal of Translational Research (discontinued), 2020, 12, 4542-4549.	0.0	22
90	RNA m6A methylation regulators in ovarian cancer. Cancer Cell International, 2021, 21, 609.	1.8	27
91	Function of N6-Methyladenosine Modification in Tumors. Journal of Oncology, 2021, 2021, 1-10.	0.6	45

# 92	ARTICLE Silencing IncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathway. Annals of Hepatology, 2022, 27, 100584.	IF 0.6	CITATIONS
93	Dynamic m6A-ncRNAs association and their impact on cancer pathogenesis, immune regulation and therapeutic response. Genes and Diseases, 2023, 10, 135-150.	1.5	5
94	ALKBH5â€mediated m6A modification of lncRNA KCNQ1OT1 triggers the development of LSCC via upregulation of HOXA9. Journal of Cellular and Molecular Medicine, 2022, 26, 385-398.	1.6	22
95	ALKBH5-mediated m6A demethylation of KCNK15-AS1 inhibits pancreatic cancer progression via regulating KCNK15 and PTEN/AKT signaling. Cell Death and Disease, 2021, 12, 1121.	2.7	33
96	The expression of m6A regulators correlated with the immune microenvironment plays an important role in the prognosis of pancreatic ductal adenocarcinoma. Gland Surgery, 2022, 11, 147-165.	0.5	5
97	Expression of lncRNA NEAT1 in endometriosis and its biological functions in ectopic endometrial cells as mediated via miR-124-3p. Genes and Genomics, 2022, 44, 527-537.	0.5	6
98	Detailed resume of RNA m6A demethylases. Acta Pharmaceutica Sinica B, 2022, 12, 2193-2205.	5.7	26
99	Analysis of N6-Methyladenosine Methylome in Adenocarcinoma of Esophagogastric Junction. Frontiers in Genetics, 2021, 12, 787800.	1.1	1
100	The Interaction Between N6-Methyladenosine Modification and Non-Coding RNAs in Gastrointestinal Tract Cancers. Frontiers in Oncology, 2021, 11, 784127.	1.3	7
101	RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential. Journal of Hematology and Oncology, 2022, 15, 8.	6.9	62
102	Advances in the functional roles of N6-methyladenosine modification in cancer progression: mechanisms and clinical implications. Molecular Biology Reports, 2022, 49, 4929-4941.	1.0	3
103	m6A-mRNA Methylation Regulates Gene Expression and Programmable m6A Modification of Cellular RNAs With CRISPR-Cas13b in Renal Cell Carcinoma. Frontiers in Genetics, 2021, 12, 795611.	1.1	5
104	Downregulation of IncRNA NEAT1 inhibits the proliferation of human cutaneous squamous cell carcinoma in vivo and in vitro. Annals of Translational Medicine, 2022, 10, 79-79.	0.7	5
105	Emerging Roles of m6A RNA Methylation Regulators in Gynecological Cancer. Frontiers in Oncology, 2022, 12, 827956.	1.3	16
106	Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification. Molecular Cancer, 2022, 21, 34.	7.9	76
107	Involvement of N6-methyladenosine modifications of long noncoding RNAs in systemic lupus erythematosus. Molecular Immunology, 2022, 143, 77-84.	1.0	13
108	Characterization of the prognostic and diagnostic values of ALKBH family members in non-small cell lung cancer. Pathology Research and Practice, 2022, 231, 153809.	1.0	6
109	m6A modification: recent advances, anticancer targeted drug discovery and beyond. Molecular Cancer, 2022, 21, 52.	7.9	138

	CITATION REI	PORT	
#	Article	IF	CITATIONS
110	ALKBH5 promotes the progression of infantile hemangioma through regulating the NEAT1/miR-378b/FOSL1 axis. Molecular and Cellular Biochemistry, 2022, 477, 1527-1540.	1.4	5
111	RNA-binding proteins and cancer metastasis. Seminars in Cancer Biology, 2022, 86, 748-768.	4.3	41
112	ALKBH5 promotes lung fibroblast activation and silica-induced pulmonary fibrosis through miR-320a-3p and FOXM1. Cellular and Molecular Biology Letters, 2022, 27, 26.	2.7	29
113	RNA demethylase ALKBH5 inhibits TCFâ€î²â€induced EMT by regulating TGFâ€î²/SMAD signaling in nonâ€small ce lungÂcancer. FASEB Journal, 2022, 36, e22283.	ell 0.2	22
114	Prognostic Value of Genomic Instability of m6A-Related IncRNAs in Lung Adenocarcinoma. Frontiers in Cell and Developmental Biology, 2022, 10, 707405.	1.8	2
115	The long and short non-coding RNAs modulating EZH2 signaling in cancer. Journal of Hematology and Oncology, 2022, 15, 18.	6.9	89
116	Identification of RNA Methylation-Related IncRNAs Signature for Predicting Hot and Cold Tumors and Prognosis in Colon Cancer. Frontiers in Genetics, 2022, 13, 870945.	1.1	10
117	Identification of Prognostic Markers of N6-Methylandenosine-Related Noncoding RNAs in Non-Small-Cell Lung Cancer. Journal of Oncology, 2022, 2022, 1-15.	0.6	2
118	Identification of Five N6-Methylandenosine-Related ncRNA Signatures to Predict the Overall Survival of Patients with Gastric Cancer. Disease Markers, 2022, 2022, 1-14.	0.6	2
119	The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer. Experimental Cell Research, 2022, 415, 113115.	1.2	8
120	Non-Coding RNA m6A Modification in Cancer: Mechanisms and Therapeutic Targets. Frontiers in Cell and Developmental Biology, 2021, 9, 778582.	1.8	25
121	The Potential Role of m6A RNA Methylation in the Aging Process and Aging-Associated Diseases. Frontiers in Genetics, 2022, 13, 869950.	1.1	19
125	Mechanism of miR-340-5p in laryngeal cancer cell proliferation and invasion through the lncRNA NEAT1/MMP11 axis. Pathology Research and Practice, 2022, , 153912.	1.0	3
126	Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine. Signal Transduction and Targeted Therapy, 2022, 7, 142.	7.1	62
127	Lens Epithelium Cell Ferroptosis Mediated with N6-Methyladenosine-Modified LncRNA and GPX4 Expression in Lens Tissue of Age-Related Cataract. SSRN Electronic Journal, 0, , .	0.4	0
129	Recent Advances of m6A Demethylases Inhibitors and Their Biological Functions in Human Diseases. International Journal of Molecular Sciences, 2022, 23, 5815.	1.8	25
130	Emerging Regulatory Mechanisms of N6-Methyladenosine Modification in Cancer Metastasis. Phenomics, 2023, 3, 83-100.	0.9	9
131	Exosome-mediated lncRNA SND1-IT1 from gastric cancer cells enhances malignant transformation of gastric mucosa cells via up-regulating SNAIL1. Journal of Translational Medicine, 2022, 20, .	1.8	10

	CHATION I	REPORT	
#	Article	IF	Citations
132	Emerging roles for IncRNA-NEAT1 in colorectal cancer. Cancer Cell International, 2022, 22, .	1.8	21
133	Novel insights into m ⁶ A modification of coding and non-coding RNAs in tumor biology: From molecular mechanisms to therapeutic significance. International Journal of Biological Sciences, 2022, 18, 4432-4451.	2.6	13
134	<scp>RNA</scp> demethylase <scp>ALKBH5</scp> regulates hypopharyngeal squamous cell carcinoma ferroptosis by posttranscriptionally activating <scp>NFE2L2</scp> / <scp>NRF2</scp> in an <scp>m⁶Aâ€IGF2BP2</scp> â€dependent manner. Journal of Clinical Laboratory Analysis, 2022, 36, .	0.9	15
135	Progress and application of epitranscriptomic m ⁶ A modification in gastric cancer. RNA Biology, 2022, 19, 885-896.	1.5	5
136	Role of m6A writers, erasers and readers in cancer. Experimental Hematology and Oncology, 2022, 11, .	2.0	49
137	M6A-related IncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma. BMC Cancer, 2022, 22, .	1.1	6
138	RNA Modifications in Gastrointestinal Cancer: Current Status and Future Perspectives. Biomedicines, 2022, 10, 1918.	1.4	5
140	<scp>m6A</scp> modification–mediated <scp>lncRNA TP53TG1</scp> inhibits gastric cancer progression by regulating <scp>CIP2A</scp> stability. Cancer Science, 2022, 113, 4135-4150.	1.7	17
141	A highâ€throughput approach to predict <scp>Aâ€toâ€l</scp> effects on <scp>RNA</scp> structure indicates a change of doubleâ€stranded content in noncoding <scp>RNAs</scp> . IUBMB Life, 2023, 75, 411-426.	1.5	2
143	Emerging role of oncogenic long noncoding RNA as cancer biomarkers. International Journal of Cancer, 2023, 152, 822-834.	2.3	14
144	ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1–Nrf2/HO-1 axis. Molecular and Cellular Biochemistry, 2023, 478, 729-741.	1.4	14
145	Epigenetic Regulation of Methylation in Determining the Fate of Dental Mesenchymal Stem Cells. Stem Cells International, 2022, 2022, 1-19.	1.2	2
146	Integrated Analyses of m6A Regulator-Based Signature on Its Clinical Application and Immunogenomic Landscape in Stomach Adenocarcinoma. BioMed Research International, 2022, 2022, 1-20.	0.9	0
147	Novel insight into the functions of N ⁶ ‑methyladenosine modified lncRNAs in cancers (Review). International Journal of Oncology, 2022, 61, .	1.4	6
148	Emerging role of N6-methyladenosine RNA methylation in lung diseases. Experimental Biology and Medicine, 2022, 247, 1862-1872.	1.1	4
149	Progress of m6A Methylation in Lipid Metabolism in Humans and Animals. Agriculture (Switzerland), 2022, 12, 1683.	1.4	2
151	Translational Regulation by eIFs and RNA Modifications in Cancer. Genes, 2022, 13, 2050.	1.0	4
152	M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma. BMC Cancer, 2022, 22, .	1.1	3

#	Article	IF	CITATIONS
153	The RNA demethylase ALKBH5 promotes the progression and angiogenesis of lung cancer by regulating the stability of the LncRNA PVT1. Cancer Cell International, 2022, 22, .	1.8	14
154	A study of RNA m6A demethylases in oral epithelial dysplasia and oral squamous cell carcinoma. Journal of Oral Biology and Craniofacial Research, 2023, 13, 111-116.	0.8	0
155	The regulatory role of N6-methyladenosine RNA modification in gastric cancer: Molecular mechanisms and potential therapeutic targets. Frontiers in Oncology, 0, 12, .	1.3	2
156	Biological and pharmacological roles of m6A modifications in cancer drug resistance. Molecular Cancer, 2022, 21, .	7.9	23
157	<scp>ALKBH5</scp> involves in osteosarcoma tumor progression by mediating Notch signaling. Precision Medical Sciences, 2023, 12, 29-36.	0.1	1
158	Identification and validation of signature for prognosis and immune microenvironment in gastric cancer based on m6A demethylase ALKBH5. Frontiers in Oncology, 0, 12, .	1.3	1
159	Heavy Ion-Responsive IncRNA EBLN3P Functions in the Radiosensitization of Non-Small Cell Lung Cancer Cells Mediated by TNPO1. Cancers, 2023, 15, 511.	1.7	3
160	Novel Insights into The Roles of N ⁶ -methyladenosine (m ⁶ A) Modification and Autophagy in Human Diseases. International Journal of Biological Sciences, 2023, 19, 705-720.	2.6	6
161	N6-methyladenosine in macrophage function: a novel target for metabolic diseases. Trends in Endocrinology and Metabolism, 2023, 34, 66-84.	3.1	11
162	The landscape of m6A regulators in esophageal cancer: molecular characteristics, immuno-oncology features, and clinical relevance. Annals of Translational Medicine, 2022, 10, 1347-1347.	0.7	1
164	Emerging role of interaction between m6A and main ncRNAs in gastrointestinal (GI) cancers. Frontiers in Immunology, 0, 14, .	2.2	0
165	Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy. Molecular Cancer, 2023, 22, .	7.9	9
166	The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: classification, mechanisms, and potential therapeutic implications. Experimental and Molecular Medicine, 2023, 55, 487-501.	3.2	5
167	LINC00659 cooperated with ALKBH5 to accelerate gastric cancer progression by stabilising JAK1 mRNA in an m ⁶ A‥THDF2â€dependent manner. Clinical and Translational Medicine, 2023, 13, .	1.7	7
168	Mutual interaction of IncRNAs and epigenetics: focusing on cancer. Egyptian Journal of Medical Human Genetics, 2023, 24, .	0.5	1
169	The role of demethylase AlkB homologs in cancer. Frontiers in Oncology, 0, 13, .	1.3	2
183	Role of N6-methyladenosine RNA modification in gastric cancer. Cell Death Discovery, 2023, 9, .	2.0	0
202	Recent Advances in RNA m6A Modification in Solid Tumors and Tumor Immunity. Cancer Treatment and Research, 2023, , 95-142.	0.2	Ο

#	Article	IF	CITATIONS
209	Emerging role of RNA modification and long noncoding RNA interaction in cancer. Cancer Gene Therapy, 0, , .	2.2	0